SOPHiA GENETICS (NASDAQ:SOPH) Hits New 52-Week High – Here’s What Happened

SOPHiA GENETICS SA (NASDAQ:SOPH)’s share price hit a new 52-week high on Wednesday . The stock traded as high as $8.01 and last traded at $7.9950, with a volume of 198496 shares changing hands. The stock had previously closed at $7.62.

Analyst Upgrades and Downgrades

SOPH has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, BTIG Research increased their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Stock Up 3.9%

The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market cap of $663.91 million, a P/E ratio of -6.88 and a beta of 0.96. The stock has a 50 day moving average price of $5.98 and a 200 day moving average price of $5.26.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Research analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $5.80, for a total value of $290,400.20. Following the transaction, the chief executive officer owned 3,601,493 shares of the company’s stock, valued at $20,888,659.40. The trade was a 1.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the sale, the insider owned 590,887 shares in the company, valued at $4,307,566.23. The trade was a 2.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 318,592 shares of company stock worth $1,952,315. Corporate insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Several large investors have recently modified their holdings of the stock. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $1,772,000. 1492 Capital Management LLC acquired a new stake in SOPHiA GENETICS during the 4th quarter worth about $973,000. Royce & Associates LP purchased a new stake in SOPHiA GENETICS during the fourth quarter valued at about $2,009,000. Hodges Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the first quarter valued at about $2,157,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of SOPHiA GENETICS in the second quarter worth about $567,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.